Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2022-10-24Clinical Trial Update: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab [Phase 4]
Clinical trial exploring hypersensitivity to CGRP as a predictive biomarker for migraine prevention with erenumab in a Phase 4 study.
-
FDA approval · 2022-10-21FDA Approved: VYEPTI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for VYEPTI (eptinezumab-jjmr) filed by Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2022-10-20FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: Acute Treatment Trial in Adult Subjects With Migraines [Phase 2, Phase 3]
Clinical trial update for an acute treatment in adults with migraines, completed phases 2 and 3 with results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Efficacy of Erenumab on Functional Impact of Migraine [Phase 4]
A Phase 4 clinical trial reported results on the efficacy of erenumab for improving functional impact in migraine.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-10-04Clinical Trial Update: Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine [Phase 2]
Phase 2 trial evaluating safety and efficacy of B244 in episodic migraine has completed with results posted.
-
FDA label_change · 2022-10-03FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for AIMOVIG (erenumab) submitted by Amgen, resulting in changes to the product labeling.
-
FDA approval · 2022-09-22FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for AIMOVIG (erenumab-aooe) submitted by Amgen Inc. The action updates the labeling to reflect t…
-
FDA approval · 2022-09-15FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Reyvow (lasmiditan) from Eli Lilly and Company.
-
FDA approval · 2022-09-06FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Sumatriptan succinate from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2022-09-06Clinical Trial Update: Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack [Phase 4]
Phase 4 pilot study evaluating IV ibuprofen for acute migraine; study completed with posted results.
-
FDA approval · 2022-08-16FDA Approved: BUTALBITAL AND ACETAMINOPHEN — Original Application (Aarkish Pharmaceuticals NJ Inc.)
FDA approved an original application for a generic butalbital and acetaminophen product from Aarkish Pharmaceuticals NJ Inc., authorizing it…
-
FDA approval · 2022-08-15FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for AIMOVIG (erenumab-aooe) from Amgen Inc, indicating an update to its indication/label.
-
CLINICAL_TRIALS trial_result · 2022-08-12Clinical Trial Update: Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine [NA]
A completed clinical trial evaluated milnacipran for reducing pain in individuals with chronic migraine; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments [Phase 3]
Phase 3 trial evaluating the efficacy and safety of eptinezumab for migraine prevention in patients not helped by prior preventive treatment…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine [Phase 4]
Phase 4 clinical trial evaluating erenumab-aooe (Aimovig) effect on disability and work productivity in employed individuals with episodic m…
-
FDA approval · 2022-07-15FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for REYVOW (lasmiditan) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users [Phase 1]
Phase 1 trial assessing how topiramate affects etonogestrel concentrations in contraceptive implant users; results completed with posted res…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine [NA]
Clinical trial update for the RIME Study evaluating combined occipital and supraorbital transcutaneous nerve stimulation for acute migraine;…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo) [NA]
A terminated clinical trial investigating mu-opioid mechanisms in migraine; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients [Phase 4]
Phase 4 trial update evaluating the safety and efficacy of oral idebenone for preventive treatment of migraine in adults.
-
FDA approval · 2022-06-22FDA Approved: SUMATRIPTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Sumatriptan succinate by Aurobindo Pharma Limited, updating an existing Sumatriptan product.
-
FDA approval · 2022-06-17FDA Approved: SUMATRIPTAN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Sumatriptan succinate from Aurobindo Pharma Limited, resulting in updated labeling for the produ…
-
CLINICAL_TRIALS trial_result · 2022-06-01Clinical Trial Update: Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. [Phase 4]
Phase 4 clinical trial evaluating reconstitution of onabotulinumtoxin A with preserved versus preservative-free saline in chronic migraine; …
-
CLINICAL_TRIALS trial_result · 2022-05-12Clinical Trial Update: Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine [Phase 3]
Extension study evaluating long-term safety and tolerability of oral atogepant for episodic migraine has completed phase 3.